What is SHINGRIX?
SHINGRIX is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:
- adults 50 years of age or older;
- adults 18 years of age or older at increased risk of HZ.1,2
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
has been added to your basket
59
UK SHINGRIX supply available now - ORDER SHINGRIX HERE
SHINGRIX is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:
SHINGRIX is contraindicated in anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX.1,2
Learn more about how SHINGRIX works
SHINGRIX is specifically formulated to address the age-related decline in shingles immunity.1-4
SHINGRIX reconstitution instructions
Instructions for reconstituting and administering SHINGRIX to your patients 50 years of age and older.1,2
Prescribing information (GB)
Prescribing information (NI)
Summary of product characteristics & Patient information leaflet (GB)
Summary of product characteristics & Patient information leaflet (NI)
References
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
PM-GB-SGX-WCNT-210006
Date of preparation: July 2021
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2021 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.